Topic: Dainippon Pharmaceutical Co. Ltd.
Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic ...
Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of ...
Japan's Dainippon Sumitomo Pharma Co. said Thursday it had agreed to buy US-based Sepracor Inc. for 2.6 billion dollars -- the latest in a string of takeovers by Japanese drugmakers expanding overseas.Japan's seventh-largest pharmaceutical company said it would launch ...
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. "We are pleased with the results of this study as these data reinforce our belief ...
The company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in 2010 - . Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from the first phase 3 clinical trial for lurasidone, which is under ...
